Stocks Health care TWST
NASDAQ · Health careTwist Bioscience Corp (TWST)
Twist Bioscience Corp brought in $431.8M of revenue over the twelve months to June 30, 2026, up 19.2% from a year earlier. It posted a net loss of $136.7M. In fiscal 2025 capital spending exceeded operating cash flow by $75.6M. At June 30, 2026 it held $117.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 3, 2026.
Key facts about Twist Bioscience Corp
- Net worth
- Twist Bioscience Corp has a market value (market cap) of $8.8B at the latest share price, and shareholders' equity of $445.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $376.6M (+20.3% year on year), with a net loss of $77.7M. Over the 12 months to June 30, 2026: revenue $431.8M, net loss $136.7M.
- Cash flow
- In fiscal 2025 operations used $47.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 3, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Twist Bioscience Corp's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Twist Bioscience Corp does
Twist Bioscience Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TWST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $376.6M | -$77.7M | -$1.30 | -$75.6M |
| 2024 | $313M | -$208.7M | -$3.60 | -$69.2M |
| 2023 | $245.1M | -$204.6M | -$3.60 | -$170.3M |
| 2022 | $203.6M | -$217.9M | -$4.04 | -$226.2M |
| 2021 | $132.3M | -$152.1M | -$3.15 | -$139.3M |
| 2020 | $90.1M | -$139.9M | -$3.57 | -$152.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TWST ranks in Health care
Latest SEC filings
What Twist Bioscience Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026Passive stake changed SCHEDULE 13G/A
- August 19, 2026Other event 8-K
- August 19, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Twist Bioscience Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $99.9M worth of shares in the last 90 days and bought none on the open market. Most of the selling (84%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Werner Robert F.Chief Accounting Officer | Sold | 148 | $20K |
| November 3, 2026 | Leproust Emily M.Chief Executive Officer, Director | Sold | 4,573 | $619.2K |
| November 3, 2026 | Green PaulaSVP of Human Resources | Sold | 1,007 | $136.3K |
| November 3, 2026 | Finn Patrick JohnPresident and COO | Sold | 2,565 | $347.3K |
| November 3, 2026 | Cho DennisSee Remarks | Sold | 949 | $128.5K |
| October 23, 2026 | Finn Patrick JohnPresident and COO | Sold | 2,245 | $302.2K |
| October 9, 2026 | Laponis AdamChief Financial Officer | Sold | 2,462 | $384.8K |
| October 5, 2026 | Leproust Emily M.Chief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,840 | $368.8K |
Who owns TWST
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 13.2% | September 8, 2026 |
| Artisan Partners Asset Management Inc.13G, passive with 3 related filers | 7.7% | August 13, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 5.8% | August 14, 2026 |
| ARK Investment Management LLC13G, passive with 1 related filers | 5.11% | September 8, 2026 |
| Vanguard Capital Management13G, passive | 5.05% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 336 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,833,891 | +279,529 |
| Artisan Partners Limited Partnership | 4,802,017 | -1,565,760 |
| Fmr LLC | 4,703,044 | +2,813,099 |
| ARK Investment Management LLC | 4,549,803 | -1,792,930 |
| State Street Corp | 3,232,532 | -438,150 |
| Vanguard Portfolio Management LLC | 2,824,989 | +175,888 |
| Vanguard Capital Management LLC | 2,699,280 | +60,236 |
| EdgePoint Investment Group Inc. | 2,521,635 | -2,860,886 |
| William Blair Investment Management, LLC | 2,174,594 | -3,095,124 |
| Farallon Capital Management, L.L.C. | 2,136,400 | +708,750 |
| Invesco Ltd. | 1,928,229 | -243,669 |
| Geode Capital Management, LLC | 1,619,361 | +99,648 |
| Goldman Sachs Group Inc | 1,408,418 | -297,128 |
| Morgan Stanley | 1,189,861 | +643,016 |
| D. E. Shaw & Co., Inc. | 1,185,605 | +1,138,961 |
| Baillie Gifford & Co | 1,086,779 | -128,372 |
| Driehaus Capital Management LLC | 1,022,526 | +437,830 |
| Sumitomo Mitsui Trust Group, Inc. | 1,000,344 | -495,755 |
| Amova Asset Management Americas, Inc. | 999,734 | -496,365 |
| Bank of America Corp | 922,647 | +338,386 |
Insiders
13 insiders reported holding 1,215,886 shares in total, about $160.7M at the last price.
| Holder | Shares |
|---|---|
| Leproust Emily M.Chief Executive Officer, Director | 558,187 |
| Finn Patrick JohnPresident and COO | 180,278 |
| Green PaulaSVP of Human Resources | 105,625 |
| Laponis AdamChief Financial Officer | 98,114 |
| Cho DennisSee Remarks | 62,840 |
| Werner Robert F.Chief Accounting Officer | 42,769 |
| Chan NelsonDirector | 33,251 |
| Ragusa Robert PDirector | 28,983 |
| Crandell KeithDirector | 27,571 |
| Starovasnik Melissa A.Director | 22,222 |
Questions about TWST
What does Twist Bioscience Corp do?
Twist Bioscience Corp is a company in the Health care sector, listed on NASDAQ as TWST. Its shares trade on NASDAQ under the ticker TWST.
What is Twist Bioscience Corp's net worth?
Twist Bioscience Corp has a market value (market cap) of $8.8B at the latest share price, and shareholders' equity of $445.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Twist Bioscience Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $136.7M on revenue of $431.8M.
How much revenue does Twist Bioscience Corp make?
Over the twelve months to June 30, 2026 Twist Bioscience Corp reported revenue of $431.8M. That is 19.2% more than a year earlier.
When did Twist Bioscience Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 3, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Twist Bioscience Corp's next earnings report?
Twist Bioscience Corp's next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TWST with
Follow TWST
Get an email when Twist Bioscience Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Twist Bioscience Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.